A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Neutropenia

Interventions

DRUG: Mavorixafor
DRUG: Placebo

Sponsor

X4 Pharmaceuticals